About Kamron Laboratories
Kamron Laboratories is a publicly listed company based in Ahmedabad (India) founded in 1990 by Kamlesh Laskari. Manufacturer of pharmaceutical and veterinary formulations. The company has 4 employees. Its chief executive, as recorded, is Kamlesh Laskari. Its Indian entity Adline Chem Lab Limited reported revenue of ₹1 Lakh. Kamron Laboratories offers products and services including Tablets, Capsules, Liquid Orals, Injectables, and Veterinary Supplements. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Kamron Laboratories is a WHO GMP and ISO certified manufacturer of tablets, capsules, liquid orals, dry syrups, eye drops and injections. It serves both domestic and international markets of pharmaceutical, veterinary formulations and educational supplements industries. It is also involved in contract manufacturing with clients such as Intas, Zydus, and Unichem. The therapeutic areas it covers are anti-infective, bone health, gastroentology care, haemostaic, multi-vitamins, pediatric care, pain and inflammation, pregnancy and reproductive care, respiratory and hepato care.
- Headquarters Ahmedabad, India
- Employees 4
- Founders Kamlesh Laskari
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website kamronlabs.com
- Social LinkedIn Facebook
- Legal Name Adline Chem Lab Limited
- Share Price₹15.79
0.00% today
- EBITDA−₹0.21 Cr
FY 2025-26
- Net Profit−₹0.29 Cr
FY 2025-26 · -123.1% YoY
- Employee Count4
Associated legal entities of Kamron Laboratories
Kamron Laboratories is associated with 2 registered companies on The Company Check; the primary company is Adline Chem Lab Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Adline Chem Lab Limited Listed CIN L35106GJ1988PLC010956 | Active | 06 Jul 1988 | Ahmedabad, Gujarat | ₹0.0 Cr | 4 | 6 | View details |
| Adline Chem Lab Limited CIN L24231GJ1988PLC010956 | 06 Jul 1988 | Ahmedabad, Gujarat, India | View details |
Products & Services of Kamron Laboratories
Kamron Laboratories offers a comprehensive portfolio of products and services, including Tablets, Capsules, Liquid Orals, Injectables, and Veterinary Supplements.
Solid form medicines for various treatments and conditions
Encapsulated drugs for oral administration
Liquid-based medicines for easy consumption
Parenteral drugs for direct administration
Products for animal care and treatment
Board of directors of Adline Chem Lab Limited (Kamron Laboratories)
Adline Chem Lab Limited is the primary company behind Kamron Laboratories. The board of Adline Chem Lab Limited currently have 4 directors; the longest-serving is Shivani Pathak, appointed in 2024. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shivani Pathak DIN 10481354 | Director | 03 Feb 2024 | 2 yrs 9 mo | Adline Chem Lab Limited |
| Dhawal Akhilesh Deopura DIN 09509762 | Director | 11 Dec 2024 | 1 yr 11 mo | Adline Chem Lab Limited |
| Nilay Jitendrabhai Vaghasiya DIN 08050673 | Director | 12 Apr 2025 | 1 yr 7 mo | Adline Chem Lab Limited |
| Vrushank Balkrushna Patel DIN 05310613 | Director | 12 Apr 2025 | 1 yr 7 mo | Adline Chem Lab Limited |
People of Kamron Laboratories
1 people are tracked at Kamron Laboratories (1 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
| Founder & CEO | Leadership |
Complete people profiles for Kamron Laboratories
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kamron Laboratories
Kamron Laboratories is a publicly listed company on the BSE with ticker symbol ADLINE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Oct 2016
- Listed onBSE: 524604
- Listed entityAdline Chem Lab Limited
- Exchange sectorHealth technology
- ISININE276T01018
- Share price₹15.79 · 2026-10-12
- Volume (last session)2,500
Financials of Kamron Laboratories
Exchange-reported figures of Adline Chem Lab Limited, the listed company behind Kamron Laboratories (BSE: ADLINE).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 6.33 | 6.59 |
| Revenue growth | - | - | - | -100.0% | -88.3% | -4.0% | - |
| EBITDA | (0.21) | (0.29) | (0.18) | (5.14) | (0.28) | (0.22) | (11.27) |
| EBITDA margin | - | - | - | - | -37.8% | -3.5% | -171.0% |
| Profit before tax | (0.33) | (0.20) | (0.30) | (4.23) | 0.69 | (1.27) | (3.50) |
| Net profit | (0.29) | (0.13) | (0.27) | 0.12 | (0.40) | (1.27) | (3.98) |
| Net profit margin | - | - | - | - | -54.1% | -20.1% | -60.4% |
| EPS (₹) | (0.48) | (0.23) | (0.46) | (7.24) | 1.23 | (2.19) | (6.44) |
| Balance sheet | |||||||
| Total assets | 0.03 | 0.00 | (0.01) | 0.06 | 4.27 | 4.79 | 6.37 |
| Net worth | (1.77) | (1.49) | (1.37) | (1.57) | 2.65 | 1.93 | 3.21 |
| Total debt | 1.80 | 1.49 | 1.36 | 1.33 | 1.32 | 2.50 | 2.85 |
| Cash & bank | 0.07 | 0.06 | 0.04 | 0.06 | 0.05 | (0.16) | 0.05 |
| Net working capital | 0.05 | 0.05 | 0.02 | 0.06 | (0.17) | 1.19 | 1.60 |
| Cash flow | |||||||
| Cash from operations | (0.16) | (0.23) | (0.17) | 0.01 | 0.21 | (0.29) | (11.34) |
| Cash from investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 11.24 |
| Cash from financing | 0.16 | 0.25 | 0.15 | 0.00 | (0.01) | (0.03) | (0.02) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.12 | 0.01 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
| Total expenses | 0.03 | 0.04 | 0.07 | 0.03 | 0.05 | 0.03 | 0.06 | 0.10 |
| EBITDA | (0.03) | (0.04) | (0.07) | (0.03) | (0.05) | (0.03) | (0.06) | (0.10) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | (0.08) | 0.03 | (0.10) | (0.07) | (0.08) | (0.06) | 0.16 | (0.13) |
| Tax | 0.01 | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) | (0.05) | (0.01) |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.12 | 0.01 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
| Total expenses | 0.03 | 0.04 | 0.07 | 0.03 | 0.05 | 0.03 | 0.06 | 0.10 |
| EBITDA | (0.03) | (0.04) | (0.07) | (0.03) | (0.05) | (0.03) | (0.06) | (0.10) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | (0.08) | 0.03 | (0.10) | (0.07) | (0.08) | (0.06) | 0.16 | (0.13) |
| Tax | 0.01 | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) | (0.05) | (0.01) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 6.33 | 6.59 |
| Revenue growth | - | - | - | -100.0% | -88.3% | -4.0% | - |
| Other income | 0.01 | 0.25 | 0.00 | 1.00 | 1.33 | 0.00 | 8.21 |
| Total expenses | 0.21 | 0.29 | 0.18 | 5.14 | 1.02 | 6.55 | 17.86 |
| Employee cost | 0.02 | 0.18 | 0.04 | 0.05 | 0.18 | 1.71 | 1.94 |
| EBITDA | (0.21) | (0.29) | (0.18) | (5.14) | (0.28) | (0.22) | (11.27) |
| EBITDA margin | - | - | - | - | -37.8% | -3.5% | -171.0% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.09 | 0.35 | 1.02 | 0.42 |
| Interest | 0.13 | 0.16 | 0.12 | 0.00 | 0.01 | 0.03 | 0.02 |
| Profit before tax | (0.33) | (0.20) | (0.30) | (4.23) | 0.69 | (1.27) | (3.50) |
| Tax | (0.04) | (0.07) | (0.03) | 0.00 | (0.05) | 0.00 | 0.26 |
| Net profit | (0.29) | (0.13) | (0.27) | 0.12 | (0.40) | (1.27) | (3.98) |
| Net profit margin | - | - | - | - | -54.1% | -20.1% | -60.4% |
| EPS (₹) | (0.48) | (0.23) | (0.46) | (7.24) | 1.23 | (2.19) | (6.44) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Reserves & surplus | (7.62) | (7.34) | (7.22) | (7.42) | (3.20) | (3.92) | (2.64) |
| Shareholders' funds (net worth) | (1.77) | (1.49) | (1.37) | (1.57) | 2.65 | 1.93 | 3.21 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 1.80 | 1.49 | 1.36 | 1.33 | 1.32 | 2.50 | 2.85 |
| Total debt | 1.80 | 1.49 | 1.36 | 1.33 | 1.32 | 2.50 | 2.85 |
| Total liabilities | - | - | (0.01) | 0.06 | 4.27 | 4.79 | 6.37 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.00 | 0.00 | 5.63 | 5.63 | 6.29 |
| Net block | 0.00 | 0.00 | 0.00 | 0.00 | 4.43 | 3.64 | 4.78 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 0.39 | 1.09 |
| Sundry debtors | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 1.58 | 1.43 |
| Cash & bank balances | 0.07 | 0.06 | 0.04 | 0.06 | 0.05 | (0.16) | 0.05 |
| Loans & advances | 0.00 | 0.01 | 0.00 | 0.00 | 0.06 | 0.17 | 0.19 |
| Total current assets | 0.07 | 0.07 | 0.04 | 0.06 | 0.44 | 1.98 | 2.76 |
| Total current liabilities | 0.02 | 0.02 | 0.02 | 0.00 | 0.61 | 0.79 | 1.16 |
| Net working capital | 0.05 | 0.05 | 0.02 | 0.06 | (0.17) | 1.19 | 1.60 |
| Total assets | 0.03 | 0.00 | (0.01) | 0.06 | 4.27 | 4.79 | 6.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.06 | 0.04 | 0.06 | 0.05 | (0.16) | 0.05 | 0.17 |
| Net cash from operating activities | (0.16) | (0.23) | (0.17) | 0.01 | 0.21 | (0.29) | (11.34) |
| Net cash from investing activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 11.24 |
| Net cash from financing activities | 0.16 | 0.25 | 0.15 | 0.00 | (0.01) | (0.03) | (0.02) |
| Net change in cash | 0.00 | 0.02 | (0.02) | 0.01 | 0.20 | (0.21) | (0.12) |
| Closing cash | 0.07 | 0.06 | 0.04 | 0.06 | 0.05 | (0.16) | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | - | - | - | -100.0% | -88.3% | -4.0% | - |
| EBITDA growth | +27.6% | -61.1% | +96.5% | -1735.7% | -27.3% | +98.1% | - |
| PBT growth | -65.0% | +33.3% | +92.9% | - | +9998.0% | +63.7% | - |
| Net income growth | -123.1% | +51.9% | -325.0% | +130.0% | +68.5% | +68.1% | - |
| Revenue CAGR (3Y) | - | -100.0% | -100.0% | -100.0% | -49.0% | -7.9% | -27.3% |
| EBITDA CAGR (3Y) | -65.6% | +1.2% | -6.5% | -23.0% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | - | - | - | - | +100.0% | -20.1% | -57.1% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | -7.4% | 0.0% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | -10.6% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 2.45 | 0.83 | 1.04 | 0.81 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -61.90 | -55.17 | -66.67 | 0.00 | -1.59 | -2.42 | -0.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 1.06 | 0.51 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 2.28 | 8.55 | 3.04 |
| Debtors turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.90 | 4.21 | 3.75 |
| EPS (₹) | (0.48) | (0.23) | (0.46) | (7.24) | 1.23 | (2.19) | (6.44) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (3.03) | (2.55) | (2.35) | (2.68) | 4.53 | 3.30 | 5.49 |
Similar companies to Kamron Laboratories
Kamron Laboratories has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Kamron Laboratories
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Kamron Laboratories (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kamron Laboratories
Complete news archive for Kamron Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kamron Laboratories
Kamron Laboratories was founded in 1990.
Kamron Laboratories is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Kamlesh Laskari is the CEO of Kamron Laboratories, as recorded in our data. They have also founded this company.
Kamron Laboratories has 4 employees.
The primary company behind Kamron Laboratories, Adline Chem Lab Limited, reported revenue of ₹1 Lakh for FY 2026, up 9997% year on year.
Kamron Laboratories is a WHO GMP and ISO certified manufacturer of tablets, capsules, liquid orals, dry syrups, eye drops and injections. It serves both domestic and international markets of pharmaceutical, veterinary formulations and educational supplements industries. It is also involved in contract manufacturing with clients such as Intas, Zydus, and Unichem. The therapeutic areas it covers are anti-infective, bone health, gastroentology care, haemostaic, multi-vitamins, pediatric care, pain and inflammation, pregnancy and reproductive care, respiratory and hepato care.
Kamron Laboratories's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Kamron Laboratories offers Tablets, Capsules, Liquid Orals, Injectables, and Veterinary Supplements.
Yes, Kamron Laboratories is publicly traded on BSE under the ticker symbol ADLINE.
Kamron Laboratories operates through Adline Chem Lab Limited.
The legal entities of Kamron Laboratories currently have 6 directors, including Dhawal Akhilesh Deopura, Shivani Pathak, Nilay Jitendrabhai Vaghasiya and others.